THANK YOU FOR SUBSCRIBING


Brian McKelligon, CEOThe CODEX (Co-detection by Indexing) technology uses an antibody comprising a unique oligonucleotide sequence, which is a part of Akoya Barcodes. The CODEX assay targets specific reporters enabling an unlimited level of flexibility in the generation of highly multiplexed panels while maintaining the tissue integrity and ensuring high-quality data. Akoya’s CODEX system is a fluidics control instrument that integrates with existing fluorescent microscopes for the synchronization of the CODEX assay and image collection. CODEX system converts a traditional fluorescent microscope into an automated, high-dimensional imaging system capable of providing in-depth analysis at a cellular and sub-cellular level. To assist with the aforementioned procedure, Akoya has developed a suite of analysis tools that enable researchers in shifting from multiplexed fluorescent images to spatially resolved cellular structure and cell phenotypes.
Akoya combines the latest technologies, algorithms, and its intuitive, easy-to-use interfaces, allowing technicians to visualize, analyze, and quantify phenotype cells labeled with multiple biomarkers.
![]()
Akoya is excited to bring unprecedented power, scale, and automation to histology through the power of multiplex immunofluorescence
Some of the other products to throw light upon are the CODEX Assay, wherein the antibody panel is run through iterative cycles. This is unlike the traditional immunofluorescence assay procedure. CODEX Assay uses the unique CODEX-based molecular barcodes and 50 customizable panels for a single-tissue straining. It provides customizable panel designs consisting of CODEX antibodies with barcodes. In order to enable the wide range of research areas and tissue-specific biomarkers, Akoya has developed the CODEX Conjugation Kit and individual CODEX Barcodes to prepare clones from third-party antibody suppliers.
“Akoya is excited to bring unprecedented power, scale, and automation to histology through the power of multiplex immunofluorescence,” says Brian McKelligon, the CEO of Akoya Biosciences. Founded in 2015 to commercialize the CODEX system, the company has reserved a spot for itself in the market for its ability to enable high-multiplexing for biomarker discovery. At this moment, Akoya’s portfolio spans the entire spectrum from powerful tools for the discovery of biomarkers that are essential to clinical research applications.
Company
Akoya Biosciences
Management
Brian McKelligon, CEO
Description
Akoya provides CODEX-based solutions for biomarker analysis and immunofluorescence tissue analysis